O que sabemos sobre antivirais com atividade contra o vírus do Mayaro in vitro?

• Autor(a) principal: Paschoalino, Marina
• Data de Publicação: 2022
• Tipo de documento: Trabalho de conclusão de curso
• Idioma: por
• Título da fonte: Repositório Institucional da UFU
• Texto Completo: https://repositorio.ufu.br/handle/123456789/34765
• topic: Febre Mayaro; Mayaro fever; Vírus Mayaro; Mayaro virus; Antiviral; Antiviral; Compostos naturais e sintéticos; Natural and synthetic compounds; Alvos virais; Viral targets; CNPQ::CIENCIAS BIOLOGICAS

Mayaro virus (MAYV) was first isolated in 1954 in Trinidad and Tobago islands, and it is the causative agent of Mayaro fever, a disease characterized by fever, rashes, headaches, myalgia, and arthralgia. The infection can progress to a chronic stage in over 50% of cases with persistent arthralgia, which can lead to disability of the infected individuals. MAYV is transmitted through the bite of the female Haemagogus spp mosquito genus. However, studies demonstrate that Aedes aegypti is also capable of transmitting it, contributing to the spread of MAYV beyond endemic areas, given the vast geographical distribution of the mosquito. Besides, the similarity of antigenic sites with other Alphavirus complicates the diagnoses of MAYV, contributing to underreporting of the disease. Nowadays, there are no antiviral drugs available to treat infected patients, being the clinical management only palliative based on analgesics and non-steroidal anti-inflammatory drugs. In this context, this review aims to summarize compounds that have demonstrated antiviral activity against MAYV in vitro, as well as discuss the potentiality of viral protein as targets for the development of drugs against MAYV. Finally, through rationalization of the data presented here in, we wish to encourage further research encompassing these compounds as potential anti-MAYV drug candidates.